Learning from adverse treatment effects
Open Access
- 1 November 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6), e630
- https://doi.org/10.1212/nxi.0000000000000630
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Ineffective treatment of PML with pembrolizumabNeurology Neuroimmunology & Neuroinflammation, 2019
- Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiencyNeurology Neuroimmunology & Neuroinflammation, 2019
- Pembrolizumab as a treatment for PML?Neurology Neuroimmunology & Neuroinflammation, 2019
- Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIgNeurology Neuroimmunology & Neuroinflammation, 2019
- Progressive multifocal leukoencephalopathyNeurology Neuroimmunology & Neuroinflammation, 2019
- Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitidesNeurology Neuroimmunology & Neuroinflammation, 2019
- Lymphocyte counts and infection ratesNeurology Neuroimmunology & Neuroinflammation, 2019
- Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitorsNeurology Neuroimmunology & Neuroinflammation, 2019